![Professor Anne Kiltie Professor Anne Kiltie](/img/200x200/staffpages/uploads/s03ak1/avatar/p7BCQfAeEtKAoM2ZOkxiWhQaMFIA9SeQGKnOC1A7.png)
MA DM DSc MRCP(UK) FRCR
Friends of ANCHOR Clinical Chair in Oncology
- About
-
- Email Address
- anne.kiltie@abdn.ac.uk
- Office Address
Room 5.053
- School/Department
- School of Medicine, Medical Sciences and Nutrition
Biography
I qualified in medicine from the Universities of Cambridge and Oxford and trained in Clinical Oncology at the Christie Hospital, Manchester, and Cookridge Hospital, Leeds. I undertook my DM at the Paterson Institute, University of Manchester and was a Clinical Research Fellow at ICRF Clare Hall before taking up a Senior Lecturer/Honorary Consultant Clinical Oncologist appointment at the University of Leeds in 2001. I moved to the Department of Oncology, University of Oxford in 2009, and obtained my DSc and personal chair in 2016.
I took up my appointment as Friends of ANCHOR Clinical Chair of Oncology at the University of Aberdeen in June 2021.
My research focusses on exploiting dietary fibre manipulation and its effects on the gut microbiome as an ‘endogenous’ means of radiosensitising tumours without increasing radiation toxicity to the surrounding normal tissues including the intestines.
Qualifications
- DSc Medical Sciences2016 - University of Oxford
- DM Medical Sciences1999 - University of Oxford
- BM BCh Medicine1988 - University of Oxford
- BA Medical Sciences1985 - University of Cambridge
- MRCP(UK) General Medicine1992 - Royal College of Physicians of England
- FRCR Clinical Oncology1995 - Royal College of Radiologists
- MA Medicine1989 - University of Cambridge
- MA Medicine1999 - University of Oxford
Memberships and Affiliations
- Internal Memberships
-
Jul 2021 - present Member of the Rowett Institute Ethics Panel
Oct 2021 - present Member of Friends of ANCHOR Research Advisory Group
- External Memberships
-
Apr 2024 - present Chair, Scottish Radiation Research Forum (ScoRRF)
Jun 2023 - present Member of RAIDER TrialTranslational Working Group
Jan 2022 - present Member of Scientific Review Group BCAN Bladder Cancer Research Innovation Award 2022
Jan 2022 - present Member of Scottish Radiotherapy Research Forum Committee
Oct 2018 - present Bladder Cancer Advocacy Network (BCAN) Bladder Cancer Research Network Management Committee
Dec 2017 - present Member of Editorial Board of European Urology Oncology
Oct 2016 - present Associate Editor of Bladder Cancer
2014 - present Grant reviewer for Italian Association for Cancer Research (AIRC)
Sept 2012 - present British Uro-oncology Group Executive Committee Trustee
Jan 2012 - present Royal College of Radiologists representative on Advisory Appointments Committees
- Research
-
Research Overview
Tumours in the pelvis, including bladder, prostate and colorectal cancer and gynaecological cancers may be treated by surgical removal or organ-preserving radiotherapy-based treatments. Current organ-preservation standard of care for most tumour sites includes addition of radiosensitising chemotherapy to improve tumour control. However, this often comes at the expense of increased radiotherapy-induced side effects to the surrounding normal tissues, including the intestines. Furthermore, such combined treatments are often not tolerated by elderly patients. With the proportion of over 75-year olds set to double by 2050, there is an urgent need to find alternative approaches to radiosensitisation.
Having worked on histone deacetylase inhibitors, which we showed to be effective tumour radiosensitisers without additional acute and late small intestinal toxicity in in vivo models, we are now working to exploit dietary fibre manipulation and the gut microbiome as an ‘endogenous’ means of radiosensitising tumours without increasing radiation toxicity to the surrounding normal tissues including the intestines.
Research Areas
Applied Health Sciences
Biomedical Sciences
Nutrition and Health
Research Specialisms
- Medicine
- Food Science
- Bacteriology
- Oncology
Our research specialisms are based on the Higher Education Classification of Subjects (HECoS) which is HESA open data, published under the Creative Commons Attribution 4.0 International licence.
Supervision
Supervisees
- MS MEREL VAN DEN HAAK
- MR ADAM POTTER
- MR DANIEL SESCU
- MISS ANAM WAJID
- Teaching
-
Teaching Responsibilities
ME3013 MBChB SSC2: supervisor
BM4501 BSc Honours project: supervisor
RN5504 Nutrition and Health through the Life Stages: lecture
RN5505 Clinical Nutrition: lecture and seminar
RN5503 Clinical Nutrition for Disease Prevention: lecture
Non-course Teaching Responsibilities
I am a Regent for the MB ChB Regent Scheme.
- Publications
-
Page 1 of 4 Results 1 to 25 of 96
Dietary fibre supplementation enhances radiotherapy tumour control and alleviates intestinal radiation toxicity
Microbiome, vol. 12, no. 1, 89Contributions to Journals: ArticlesHow do tumours outside the gastrointestinal tract respond to dietary fibre supplementation?
BMJ Oncology, vol. 2, no. 1, e000107Contributions to Journals: Review articlesField-cycling imaging in ovarian cancer: a novel technology
International Journal of Gynecological Cancer, vol. 33, no. 8, pp. 1329-1330Contributions to Journals: Comments and DebatesGenome-wide Association Study of Bladder Cancer Reveals New Biological and Translational Insights
European Urology, vol. 84, no. 1, pp. 127-137Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1016/j.eururo.2023.04.020
- [ONLINE] View publication in Scopus
Exploiting dietary fibre and the gut microbiota in pelvic radiotherapy patients
British Journal of Cancer, vol. 127, pp. 2087–2098Contributions to Journals: Review articlesImmunofluorescence microscopy-based detection of ssDNA foci by BrdU in mammalian cells
STAR Protocols, vol. 2, no. 4, 100978Contributions to Journals: ArticlesThe role of dietary supplements, including biotics, glutamine, polyunsaturated fatty acids and polyphenols, in reducing gastrointestinal side effects in patients undergoing pelvic radiotherapy: A systematic review and meta-analysis
Clinical and Translational Radiation Oncology, vol. 29, pp. 11-19Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1016/j.ctro.2021.04.006
- [OPEN ACCESS] http://aura.abdn.ac.uk/bitstream/2164/16677/1/Bartsch_etal_the_role_of_VOR.pdf
- [ONLINE] View publication in Scopus
Evaluation of Loading Strategies to Improve Tumor Uptake of Gemcitabine in a Murine Orthotopic Bladder Cancer Model Using Ultrasound and Microbubbles
Ultrasound in Medicine and Biology, vol. 47, no. 6, pp. 1596-1615Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1016/j.ultrasmedbio.2021.02.001
- [ONLINE] View publication in Scopus
p97/VCP inhibition causes excessive MRE11-dependent DNA end resection promoting cell killing after ionizing radiation
Cell Reports, vol. 35, no. 8, 109153Contributions to Journals: ArticlesUltrasound-Mediated Gemcitabine Delivery Reduces the Normal-Tissue Toxicity of Chemoradiation Therapy in a Muscle-Invasive Bladder Cancer Model
International Journal of Radiation Oncology Biology Physics, vol. 109, no. 5, pp. 1472-1482Contributions to Journals: ArticlesSPRTN protease-cleaved MRE11 decreases DNA repair and radiosensitises cancer cells
Cell Death and Disease, vol. 12, no. 2, 165Contributions to Journals: ArticlesGreater utility of molecular subtype rather than epithelial-to-mesenchymal transition (EMT) markers for prognosis in high-risk non-muscle-invasive (HGT1) bladder cancer
Journal of Pathology: Clinical Research, vol. 6, no. 4, pp. 238-251Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1002/cjp2.167
- [OPEN ACCESS] http://aura.abdn.ac.uk/bitstream/2164/17424/1/Ottley_etal_JPCR_Greater_utility_of_VOR.pdf
- [ONLINE] View publication in Scopus
Association of Bacteroides acidifaciens relative abundance with high-fibre diet-associated radiosensitisation
BMC Biology, vol. 18, 102Contributions to Journals: ArticlesThe Histone Deacetylase Inhibitor Romidepsin Spares Normal Tissues While Acting as an Effective Radiosensitizer in Bladder Tumors in Vivo
International Journal of Radiation Oncology Biology Physics, vol. 107, no. 1, pp. 212-221Contributions to Journals: ArticlesEAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort: Under the Auspices of the EAU-ESMO Guidelines Committees
European Urology, vol. 77, no. 2, pp. 223-250Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1016/j.eururo.2020.03.017
- [OPEN ACCESS] http://aura.abdn.ac.uk/bitstream/2164/15380/1/EAU_ESMO_Bladder_Cancer_Consensus_Eur_Urol_MANUSCRIPT_AND_TABLES_AAM.pdf
- [OPEN ACCESS] http://aura.abdn.ac.uk/bitstream/2164/15380/2/EAU_ESMO_Bladder_Cancer_Consensus_Eur_Urol_SI_Appendix_AAM.pdf
The p97–Ataxin 3 complex regulates homeostasis of the DNA damage response E3 ubiquitin ligase RNF8
EMBO Journal, vol. 38, no. 21, e102361Contributions to Journals: ArticlesMRE11A Isoform Expression Associated with Outcome Following Radiotherapy in Muscle-Invasive Bladder Cancer does not Alter Cell Survival and DNA Double-Strand Break Repair Following Ionising Radiation
Bladder Cancer, vol. 5, no. 2, pp. 147-157Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.3233/BLC-190209
- [ONLINE] View publication in Scopus
MRE11 as a Predictive Biomarker of Outcome After Radiation Therapy in Bladder Cancer
International Journal of Radiation Oncology Biology Physics, vol. 104, no. 4, pp. 809-818Contributions to Journals: ArticlesMouse Models of Muscle-invasive Bladder Cancer: Key Considerations for Clinical Translation Based on Molecular Subtypes
European Urology Oncology, vol. 2, no. 3, pp. 239-247Contributions to Journals: Review articles- [ONLINE] DOI: https://doi.org/10.1016/j.euo.2018.08.014
- [ONLINE] View publication in Scopus
Utility of Bladder-Sparing Therapy vs Radical Cystectomy for Muscle-Invasive Bladder Cancer
JAMA Surgery, vol. 154, no. 2, pp. 185-186Contributions to Journals: Letters- [ONLINE] DOI: https://doi.org/10.1001/jamasurg.2018.4370
- [ONLINE] View publication in Scopus
Neoadjuvant treatment for muscle-invasive bladder cancer: The past, the present, and the future
Urologic Oncology: Seminars and Original Investigations, vol. 36, no. 9, pp. 413-422Contributions to Journals: Review articles- [ONLINE] DOI: https://doi.org/10.1016/j.urolonc.2017.10.014
- [ONLINE] View publication in Scopus
Recommendations for follow-up of muscle-invasive bladder cancer patients: A consensus by the international bladder cancer network
Urologic Oncology: Seminars and Original Investigations, vol. 36, no. 9, pp. 423-431Contributions to Journals: Review articles- [ONLINE] DOI: https://doi.org/10.1016/j.urolonc.2018.01.014
- [ONLINE] View publication in Scopus
Harnessing citizen science through mobile phone technology to screen for immunohistochemical biomarkers in bladder cancer
British Journal of Cancer, vol. 119, no. 2, pp. 220-229Contributions to Journals: ArticlesContemporary Patterns of Multidisciplinary Care in Patients With Muscle-invasive Bladder Cancer
Clinical genitourinary cancer, vol. 16, no. 3, pp. 213-218Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1016/j.clgc.2017.11.004
- [ONLINE] View publication in Scopus
High Levels of Patient Satisfaction in Joint Uro-oncology Clinics to Assist Patient Choice in Early Prostate Cancer and Muscle-invasive Bladder Cancer
Clinical Oncology, vol. 30, no. 4, pp. e39Contributions to Journals: Letters- [ONLINE] DOI: https://doi.org/10.1016/j.clon.2018.01.004
- [ONLINE] View publication in Scopus